دورية أكاديمية

Patient Perceptions of Three Substance Use Screening Tools for Use During Pregnancy.

التفاصيل البيبلوغرافية
العنوان: Patient Perceptions of Three Substance Use Screening Tools for Use During Pregnancy.
المؤلفون: Trocin KE; Battelle Memorial Institute, Baltimore, USA., Oga EA; Battelle Memorial Institute, Baltimore, USA.; RTI International, Rockville, USA., Mulatya C; The Emmes Company, LLC, Rockville, USA., Mark KS; University of Maryland School of Medicine, Baltimore, USA., Coleman-Cowger VH; Battelle Memorial Institute, Baltimore, USA. vcolemancowger@emmes.com.; The Emmes Company, LLC, Rockville, USA. vcolemancowger@emmes.com.; University of Maryland School of Medicine, Baltimore, USA. vcolemancowger@emmes.com.
المصدر: Maternal and child health journal [Matern Child Health J] 2022 Jul; Vol. 26 (7), pp. 1488-1495. Date of Electronic Publication: 2022 Apr 24.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 9715672 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-6628 (Electronic) Linking ISSN: 10927875 NLM ISO Abbreviation: Matern Child Health J Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : New York, NY : Kluwer Academic/Plenum Publishers
Original Publication: New York : Plenum Press, c1997-
مواضيع طبية MeSH: Pregnancy Complications*/diagnosis , Substance-Related Disorders*/diagnosis, Female ; Humans ; Mass Screening/methods ; Pregnancy ; Pregnant Women/psychology ; Prenatal Care
مستخلص: Objectives: The purpose of this study was to understand pregnant women's perceptions of three validated substance use screening tools and identify a preferred tool for use during pregnancy. The three screening tools studied included the 4P's Plus, the NIDA Quick Screen/ NIDA-Modified Alcohol, Smoking and Substance Involvement Screening Test, and the Substance Use Risk Profile-Pregnancy Scale.
Methods: A total of 493 cognitive interviews were completed with a diverse sample of pregnant women presenting to two obstetrics practices in Baltimore, MD from January 2017 to January 2018. This study served as a qualitative companion to a larger study comparing the accuracy and acceptability of substance use screening tools in prenatal care. After completing each screening tool, participants were asked their perceptions of the tool and to choose their preferred tool. Interviews were recorded, transcribed verbatim, coded, and analyzed using NVivo software.
Results: The plurality of participants (43.4%) reported they preferred the 4P's Plus. Fewer participants preferred the NIDA Quick Screen (32.5%) and the SURP-P (24.1%). Participants felt that the 4P's Plus was both comprehensive and concise. While many participants felt that disclosure of substance use would vary by individual, participants also suggested that when screening is confidential, includes questions about a patient's background, and administered by a non-judgmental provider, pregnant people may be more likely to answer honestly.
Conclusions for Practice: The 4P's Plus is a promising and acceptable substance use screening tool for use in prenatal care. Clinicians can use several methods to increase acceptability of substance use screening and encourage disclosure of prenatal substance use.
(© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References: American College of Obstetricians and Gynecologists. (2017). Opioid use and opioid use disorder in pregnancy. Committee opinion No. 711. Obstetrics & Gynecology, 130(2), e81–e94. (PMID: 10.1097/AOG.0000000000002235)
Chang, J. C., Holland, C. L., Tarr, J. A., Rubio, D., Rodriguez, K. L., Kraemer, K. L., et al. (2017). Perinatal illicit drug and marijuana use: An observational study examining prevalence, screening, and disclosure. American Journal of Health Promotion, 31(1), 35–42. (PMID: 10.4278/ajhp.141215-QUAL-625)
Chasnoff, I. J., McGourty, R. F., Bailey, G. W., Hutchins, E., Lightfoot, S. O., Pawson, L. L., et al. (2005). The 4P’s Plus© screen for substance use in pregnancy: Clinical application and outcomes. Journal of Perinatology, 25(6), 368–374. (PMID: 10.1038/sj.jp.7211266)
Chasnoff, I. J., Wells, A. M., McGourty, R. F., & Bailey, L. K. (2007). Validation of the 4P’s Plus© screen for substance use in pregnancy validation of the 4P’s Plus. Journal of Perinatology, 27(12), 744–748. (PMID: 10.1038/sj.jp.7211823)
Coleman-Cowger, V. H., Oga, E. A., Peters, E. N., Trocin, K., Koszowski, B., & Mark, K. (2018). Comparison and validation of screening tools for substance use in pregnancy: A cross-sectional study conducted in Maryland prenatal clinics. British Medical Journal Open, 8(2), e020248.
Coleman-Cowger, V. H., Oga, E. A., Peters, E. N., Trocin, K. E., Koszowski, B., & Mark, K. (2019). Accuracy of three screening tools for prenatal substance use. Obstetrics and Gynecology, 133(5), 952. (PMID: 10.1097/AOG.0000000000003230)
Howell, M. P., Smith, A. M., Lindsay, E. B., & Drury, S. S. (2019). Understanding barriers to timely identification of infants at risk of neonatal opiate withdrawal syndrome. The Journal of Maternal-Fetal & Neonatal Medicine, 34, 1161. (PMID: 10.1080/14767058.2019.1627316)
Humeniuk, R., Ali, R., Babor, T. F., Farrell, M., Formigoni, M. L., Jittiwutikarn, J., et al. (2008). Validation of the alcohol, smoking and substance involvement screening test (ASSIST). Addiction, 103(6), 1039–1047. (PMID: 10.1111/j.1360-0443.2007.02114.x)
Jones, H. E. (2005). The challenges of screening for substance use in pregnant women: Commentary on the 4P’S plus tool. Journal of Perinatology, 25(6), 365–367. (PMID: 10.1038/sj.jp.7211293)
National Institute of Mental Health. (2020). Substance use whole pregnant and breastfeeding. National Institutes of Health. Retrieved August 3, 2020 from https://www.drugabuse.gov/publications/substance-use-in-women/substance-use-while-pregnant-breastfeeding .
Roberts, S. C., & Nuru-Jeter, A. (2010). Women’s perspectives on screening for alcohol and drug use in prenatal care. Women’s Health Issues: Official Publication of the Jacobs Institute of Women’s Health, 20(3), 193–200. https://doi.org/10.1016/j.whi.2010.02.003. (PMID: 10.1016/j.whi.2010.02.003)
Stone, R. (2015). Pregnant women and substance use: Fear, stigma, and barriers to care. Health & Justice, 3(1), 2. (PMID: 10.1186/s40352-015-0015-5)
Substance Abuse and Mental Health Services Administration. (2019). 2018 NSDUH Detailed Tables. U.S. Department of Health and Human Services. Retrieved August 3, 2020 from https://www.samhsa.gov/data/report/2018-nsduh-detailed-tables .
Tong, A., Sainsbury, P., & Craig, J. (2007). Consolidated criteria for reporting qualitative research (COREQ): A 32-item checklist for interviews and focus groups. International Journal for Quality in Health Care, 19(6), 349–357. https://doi.org/10.1093/intqhc/mzm042. (PMID: 10.1093/intqhc/mzm04217872937)
Trocin, K. E., Weinstein, N. I., Oga, E. A., Mark, K. S., & Coleman-Cowger, V. H. (2020). Prenatal practice staff perceptions of three substance use screening tools for pregnant women. Journal of Addiction Medicine, 14(2), 139–144. (PMID: 10.1097/ADM.0000000000000543)
U.S. Preventive Services Task Force (USPSTF). (2020). Unhealthy drug use: Screening. Published Final Recommendations. U.S. Preventive Services Task Force. Retrieved August 3, 2020 from https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/drug-use-illicit-screening.
World Health Organization (WHO). (2014). Guidelines for identification and management of substance use and substance use disorders in pregnancy. (ISBN: 9789241548731). WHO. Retrieved August 3, 2020 from https://www.who.int/publications/i/item/9789241548731.
Yonkers, K. A., Gotman, N., Kershaw, T., Forray, A., Howell, H. B., & Rounsaville, B. J. (2010). Screening for prenatal substance use: Development of the substance use risk profile-pregnancy scale. Obstetrics and Gynecology, 116(4), 827. (PMID: 10.1097/AOG.0b013e3181ed8290)
معلومات مُعتمدة: R01DA041328 United States DA NIDA NIH HHS; R01DA041328 United States DA NIDA NIH HHS
فهرسة مساهمة: Keywords: Pregnancy; Prenatal care; Qualitative research; Screening; Substance use
تواريخ الأحداث: Date Created: 20220424 Date Completed: 20220609 Latest Revision: 20220609
رمز التحديث: 20231215
DOI: 10.1007/s10995-022-03442-1
PMID: 35461364
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-6628
DOI:10.1007/s10995-022-03442-1